Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 794 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Studies Test CAR T-Cell Therapies Designed to Overcome Key Limitations February 8, 2023 A Safer, Better Treatment Option for Some Younger Women with Breast... January 11, 2023 Overall Survival Significantly Longer with Darolutamide in Non-metastatic CRPC September 14, 2020 What Are Biosimilars in Cancer Treatment? September 15, 2020 Load more HOT NEWS Trastuzumab Deruxtecan Leads to Longer PFS and OS Compared with Chemotherapy... Severe Immune-Related Gastroenterocolitis Described After in Utero Exposure to Pembrolizumab Clinical and Biological Activity of Patritumab Deruxtecan in Patients with HR-positive,... Neoadjuvant Ipilimumab Plus Nivolumab Results in Longer EFS Than Adjuvant Nivolumab...
